Table 1 Patient characteristics
Characteristic | Overall, N = 274 (%) | Adjuvant, N = 42(%) | Curative, N = 232 (%) |
|---|---|---|---|
Age | |||
Median (Range) | 32(18—62) | 36(18—62) | 31(18–60) |
ECOG | |||
0 | 238 (86.86%) | 41 (97.62%) | 197(84.91%) |
1 | 30 (10.95%) | 1 (2.38%) | 29(12.5%) |
2 | 6(2.19%) | 0 (0.00) | 6 (2.59%) |
Smoking history | |||
No | 218 (79.56%) | 34 (80.95%) | 184 (79.31%) |
Yes | 56 (20.44%) | 8 (19.05%) | 48 (20.69%) |
Histology | |||
Seminoma | 100 (36.50%) | 24 (57.14%) | 76 (32.76%) |
Non seminoma | 174 (63.50%) | 18 (42.86%) | 156 (67.24%) |
Primary site | |||
Testis | 201 (73.36%) | 42 (100.00%) | 159 (68.53%) |
Retroperitoneum | 34 (12.41%) | 0 (0.00%) | 34 (14.66%) |
Mediastinum | 39 (14.23%) | 0 (0.00) | 39 (16.81%) |
Metastatic sites | |||
Abdominal lymph nodes | 155 (56.57%) | 4 (9.52%) | 151 (65.09%) |
Mediastinal lymph nodes | 22 (8.03%) | 0 (0.00) | 22 (9.48%) |
Supraclavicular lymph nodes | 26 (9.49%) | 0 (0.00) | 26 (11.21%) |
Lung metastases | 70 (25.55%) | 0 (0.00) | 70 (30.17%) |
Liver metastases | 11 (4.01%) | 0 (0.00) | 11 (4.74%) |
Bone metastases | 9 (3.28%) | 0 (0.00) | 9 (3.88%) |
Brain metastases | 5 (1.82%) | 0 (0.00) | 5 (2.16%) |
Other | 20 (7.30%) | 0 (0.00) | 20 (8.62%) |
Presence of NPVM | |||
Yes | 37 (13.50%) | 0 (0.00) | 37 (15.95%) |
No | 237 (86.50%) | 42 (100.00%) | 195 (84.05%) |
IGCCCG prognostic groups | |||
Good | 120 (43.80%) | 8 (19.05%) | 112 (48.28) |
Intermediate | 63 (22.99%) | 0 (0.00) | 63 (27.16) |
Poor | 57 (20.80%) | 0 (0.00) | 57 (24.57) |
Serum tumor markers | |||
S0 | 91 (33.21%) | 42 (100.00%) | 49 (21.12%) |
S1 | 84 (30.66%) | 0 (0.00) | 84 (36.21%) |
S2 | 71 (25.91%) | 0 (0.00) | 71 (30.60%) |
S3 | 28 (10.22%) | 0 (0.00) | 28 (12.07%) |
Total | 274(100.00) | 42(15.33%) | 232((84.67%) |